GW842166X 25 mg | 99.88%
TargetMol
GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2.
More Information Supplier PageGW842166X
Search Results
Rucaparib 2 mg | Purity Not Available
TargetMol
Rucaparib is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP.
More Information Supplier PageRucaparib
Rucaparib 5 mg | Purity Not Available
TargetMol
Rucaparib is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP.
More Information Supplier PageRucaparib
Rucaparib 10 mg | Purity Not Available
TargetMol
Rucaparib is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP.
More Information Supplier PageRucaparib
Rucaparib 25 mg | Purity Not Available
TargetMol
Rucaparib is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP.
More Information Supplier PageRucaparib
Rucaparib 50 mg | Purity Not Available
TargetMol
Rucaparib is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP.
More Information Supplier PageRucaparib
Rucaparib 100 mg | Purity Not Available
TargetMol
Rucaparib is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP.
More Information Supplier PageRucaparib
6-Mercaptopurine 100 mg | 99.94%
TargetMol
Mercaptopurine is an antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
More Information Supplier Page6-Mercaptopurine 500 mg | 99.94%
TargetMol
Mercaptopurine is an antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
More Information Supplier PageSC-514 10 mg | 99.88%
TargetMol
SC-514 (GK 01140) is a selective, orally active, ATP-competitive IKK-2 inhibitor (IC50=11.2±4.7 μM), obstructs NF-κB-dependent gene expression.
More Information Supplier PageSC-514
